10-K
Annual Report
DAY ONE BIOPHARMACEUTICALS, INC.
DAWN
NASDAQ
CIK: 1845337
File #: 001-40431
Balance Sheet
38 line items · 2 periods
XBRL
| Item | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|
Current assets: | ||
Cash and cash equivalents | 124,968,000 | 230,784,000 |
US Treasury Securities | 12,947,000 | 110,645,000 |
Money Market Funds | 16,728,000 | 47,003,000 |
U.S. government agency securities | 75,163,000 | 63,202,000 |
Cash Equivalents | 104,838,000 | 220,850,000 |
Short-term investments | 406,752,000 | 135,563,000 |
Accounts receivable, net | 13,876,000 | 0 |
Inventory | 3,321,000 | 0 |
Prepaid expenses and other current assets | 13,413,000 | 8,927,000 |
Total current assets | 562,330,000 | 375,274,000 |
Property and equipment, net | 2,285,000 | 208,000 |
Operating lease right-of-use asset | 2,422,000 | 352,000 |
Intangible assets, net | 15,630,000 | 0 |
Deposits and other long-term assets | 121,000 | 214,000 |
Total assets | 582,788,000 | 376,048,000 |
Liabilities and stockholders' equity | ||
Current liabilities: | ||
Accounts payable | 3,262,000 | 2,576,000 |
Accrued expenses and other current liabilities | 68,625,000 | 26,524,000 |
Current portion of deferred revenue | 1,554,000 | 0 |
Current portion of operating lease liabilities | 10,000 | 408,000 |
Total current liabilities | 73,451,000 | 29,508,000 |
Long-term portion of deferred revenue | 3,233,000 | 0 |
Long-term portion of operating lease liabilities | 2,592,000 | 0 |
Other long-term liability | 761,000 | 0 |
Total liabilities | 80,037,000 | 29,508,000 |
Stockholders' equity | ||
Common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 101,116,162 and 87,227,132 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 10,000 | 9,000 |
Additional paid-in-capital | 1,056,738,000 | 805,107,000 |
Accumulated other comprehensive income | 84,000 | 9,000 |
Accumulated deficit | (554,081,000) | (458,585,000) |
Total stockholders' equity | 502,751,000 | 346,540,000 |
Accumulated Other Comprehensive Loss | 84,000 | 9,000 |
Additional Paid-in Capital | 1,056,738,000 | 805,107,000 |
Accumulated Deficit | (554,081,000) | (458,585,000) |
Common Shares | 10,000 | 9,000 |
Total liabilities and stockholders' equity | 582,788,000 | 376,048,000 |